FIELD: chemistry.SUBSTANCE: invention relates to compounds of formula I:or pharmaceutically acceptable salts thereof, in which Q is a divalent or trivalent radical selected from C6-10aryl and heteroaryl； where said aryl or heteroaryl in Q is optionally substituted up to 3 times with radicals independently selected from halogen, C1-6 alkyl, C1-6 alkyl substituted with halogen, C1-6 alkoxy group, C1-6 alkoxy group substituted with halogen, -C(O)R20 and -C(O)OR20； where R20 is selected from hydrogen and C1-6 alkyl； and where optionally, the carbon atom neighbouring W2 can be bonded through CR31 or O with a carbon atom of Q to form a 5-member ring condensed with A and Q rings； where R31 is selected from hydrogen and C1-6 alkyl； W1 and W2 are independently selected from CR21 and N； where R21 is selected from hydrogen and -C(O)OR25； where R25 denotes hydrogen； ring A can contain up to 2 carbon ring atoms substituted with a group selected from -C(O)-, -C(S)- and -C(=NOR30)- and can be partially unsaturated and contain up to 2 double bonds； where R30 denotes hydrogen ； L is selected from C1-6alkylene, C2-6alkenylene, -OC(O)(CH2)n-, -NR26(CH2)n- and -O(CH2)n-； where R26 is selected from hydrogen and C1-6 alkyl； where n is selected from 0, 1, 2, 3 and 4； q is selected from 0 and 1； t1, t2, t3 and t4 are each independently selected from 0, 1 and 2； R1 is selected from -X1S(O)0-2X2R6a, -X1S(O)0-2X2OR6a, -X1S(O)0-2X2C(O)R6a, -X1S(O)0-2X2C(O)OR6a, -X1S(O)0-2X2OC(O)R6a and -X1S(O)0-2NR6aR6b； where X1 is selected from a bond, O, NR7a and C1-4alkylene； where R7a is selected from hydrogen and C1-6alkyl； X2 is selected from a bond and C1-6alkylene； R6a is selected from hydrogen, cyanogroup, halogen, C1-6alkyl, C2-6alkenyl, C6-10aryl, heteroaryl, heterocycloalkyl and C3-8cycloalkyl； where said aryl, heteroaryl, cycloalkyl and heterocycloalkyl in R6a is optionally substituted with 1-3 radicals independently selected from hydroxy group, halogen, C1-6alkyl, C1-6alkyl substituted with a cy
